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ess: kpsazakis@hol.gr (Summary The introduction of infliximab, an anti-TNF-a agent, in the treatment of
rheumatic diseases has offered important therapeutic advances in recent years. The
main adverse effect from the usage of this drug is susceptibility to infections, mainly
reactivation of latent tuberculosis. We present a 23 year-old male with ankylosing
spondylitis, who developed endobronchial and widespread pulmonary tuberculosis, 2
years after initiation of treatment with infliximab. The patient had already been
treated for a positive PPD skin test with a 9-month prophylactic course of isoniazid.
He was treated with a five drug anti-tuberculosis scheme but he showed an
extremely slow therapeutic response with daily high fever, even 4 months after
initiation of treatment. Seven months after beginning anti-tuberculosis therapy,
bronchoscopy still revealed necrotic and inflammatory tissue at the site of the
original lesions. This unusual clinical course of tuberculosis infection was attributed
to immunosuppression due to the long-lasting anti-TNF-a action of infliximab.
& 2004 Elsevier Ltd. All rights reserved.Introduction
The introduction of anti-TNF-a agents in recent
years, has proven very effective in the treatment of
chronic inflammatory disorders, such as rheumatoid
arthritis, Crohn’s disease, chronic juvenile arthri-
tis, ankylosing spondylitis and psoriasis with or
without arthritis.1,2 Patients with such disorders,
who were resistant to conventional immunomodu-Elsevier Ltd. All rights reserv
+30 210 6435278; fax:
K. Psathakis).latory treatment, have dramatically improved with
the use of anti-TNF-a regimens. Within a few years
since the introduction of these drugs into clinical
practice, a wide range of infections have been
reported, which were attributed to the use of these
agents.3,4 The reactivation of a latent tuberculosis
(TB) infection has been recognized to be the most
serious side-effect and it has been determined that
patients with a positive PPD skin test should be
treated for latent TB before they are given any
anti-TNF-a agent.5
In the case we are presenting, previous therapy
for latent TB failed to protect our patient from aed.
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treatment has significantly modified the course of
the expected response to anti-TB therapy.Figure 1 A chest radiograph on admission reveals
micronodular shadows on the right upper lung field and
all over the left lung, as well as consolidation with air
bronchogram on the left lower lobe.
Figure 2 A CT scan of the chest on admission shows
micronodular shadows mainly in the left lung and
consolidation on the left lower lobe with a small pleural
effusion on the same side (middle lung fields).Case report
A 23-year-old male, with a history of severe
ankylosing spondylitis, was admitted to the Rheu-
matology department of our hospital because of
fever (39 1C) and dry cough that had begun the
previous day. The patient had a 5-year history of
ankylosing spondylitis, disproportionately advanced
for his age, with ankylosis of the cervical region of
the vertebral column, severe reduction of the
motility of the trunk with kyphosis, fixation of the
thorax at high lung volumes and sacroiliitis. In the
past, he had been treated with sulfasalazine and
then with methotrexate with no improvement. Due
to the lack of clinical response, infliximab (an anti-
TNF-a agent) was administered intravenously at a
dose of 5mg/kg body weight every 2 months,
following three initial loading doses (0, 2nd, 6th
week). The patient responded dramatically to the
new treatment. The biological inflammatory in-
dexes (initial erythrocyte sedimentation rate—ESR
90mm/h and C-reactive protein—CRP 50mg/L)
returned to their normal levels soon after initiation
of therapy and remained normal thereafter. At the
time of admission, the patient had completed 2
years of therapy with infliximab and methotrexate.
The last dose of infliximab had been given 10 days
before hospitalization. Prior to the initiation of
infliximab, the patient had a positive PPD skin test
(11mm) and a normal chest radiograph. Isoniazid
300mg daily, as a prophylactic treatment for latent
TB infection, had been given for 9 months.
On admission, auscultation of his chest revealed
bronchial sound at the base of the left lung and
rales all over the lung fields. A chest radiograph
showed coalescent micronodular shadows at the
right upper lung field and all over the left lung as
well as consolidation with air bronchogram in the
left lower lobe (Fig. 1).
A laboratory work-up revealed anemia (Hemato-
crit: 33%), high ESR (113mm/h) and CRP (180mg/L)
and no other abnormal findings. The response to a
PPD skin test was measured at 9mm. Computed
tomography (CT) scan of the chest revealed
micronodular shadows, mainly on the left lung,
and consolidation on the left lower lobe with a
small pleural effusion on the same side (Figs. 2 and
3). Bronchoscopy was performed, which revealed a
diffusely inflamed bronchial mucosa on the left
with edema and partial obstruction of the apical
segmental bronchus of the left lower lobe. Thesefindings were consistent with endobronchial TB. A
bronchoalveolar lavage (BAL) was performed on the
apical segment of the left lower lobe and endo-
bronchial biopsies were taken from the area. The
diagnosis of TB was established with positive AFB
(acid-fast bacillus) stains and PCR on BAL fluid.
Endobronchial biopsies revealed caseating granulo-
mas. Anti-TB therapy was initiated promptly with
isoniazid, rifampin, ethambutol and streptomycin.
The patient was negative for HIV1/2.
The patient initially responded well to treat-
ment. His fever resolved, at first, within days
however he again developed a low grade and then a
high fever (39.5 1C). A new chest radiograph
showed further extension of nodular and alveolar
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Figure 4 Bronchoscopy, 7 months after initiation of anti-
TB therapy, revealed grayish necrotic inflammatory tissue
at the opening of the apical bronchus of the left lower
lobe.
Figure 3 A CT scan of the chest on admission shows
micronodular shadows mainly in the left lung and
consolidation on the left lower lobe with a small pleural
effusion on the same side (lower lung fields).
E. Vlachaki et al.650shadows to new areas and further increase of the
consolidated area of the left lower lobe. A new CT
scan of the chest 20 days after initiation of
treatment showed atelectasis and consolidation of
the left lower lobe with further increase of the
pleural effusion. Bronchoscopy was performed
again, which revealed obstruction of the apical
segmental bronchus of the left lower lobe. BAL was
performed and new endobronchial biopsies were
taken from the area. The patient’s daily tempera-
ture reached steadily to the level of 38.6–39.7 1C
with poor response to anti-pyretic drugs. Because
of the patient’s deterioration, pyrazinamide was
added to the anti-TB regimen. Intravenous cefe-
pime was also given for 10 days, to cover for the
possibility of a super-infection of the obstructed
lung segment.
AFB stains on BAL fluid of the second broncho-
scopy were negative but the culture was positive.
Mycobacterium tuberculosis was identified, that
was sensitive to all the primary anti-TB drugs. All
bacterial and fungal cultures of the BAL fluid, as
well as blood cultures were negative. Forty days
after the initiation of anti-TB treatment, the
patient began to show some improvement of his
symptoms but he continued to have high fever. His
fever did not begin to resolve until after 3 months
on anti-TB treatment. At this time, a new CT scan
of the chest revealed a significant improvement of
all the radiographic lesions. A new bronchoscopy
showed decreased inflammation and edema at the
origin of the apical segmental bronchus of the left
lower lobe. BAL was performed again. AFB stains
and culture for M. tuberculosis of the BAL fluid
were both negative. At the same period of time
(about 3 months after the last dose of infliximab),the patient developed severe low-back pain,
mainly at night. Radiographic evaluation and a
technetium—Tc99 MDP bone scan did not reveal any
signs of a suspected TB bone lesion. The symptoms
were attributed to recurrence of ankylosing spon-
dylitis and indomethacin 150mg bid per os was
given to relieve the patient’s symptoms.
The following months, the patient’s fever sub-
sided, as he gradually improved, both clinically and
radiographically. A bronchoscopic re-evaluation 7
months after initiation of therapy revealed further
improvement of the lesions at the entrance of the
apical segmental bronchus of the left lower lobe,
but there was still a partial obstruction by necrotic
tissue (Fig. 4).
The patient received a total dose of 70 g of
streptomycin and completed 4 months on etham-
butol and pyrazinamide. Treatment with isoniazid
and rifampin was given for a total of 15 months.
The latest bronchoscopy on month 12 was free of
active lesions. Cultures done on tissue specimens
and bronchial washings from the area were nega-
tive for M. tuberculosis. Despite these findings, we
decided that anti-TNF-a treatment should not be
given again to this patient, even though his
ankylosing spondylitis had relapsed and clinically
appeared to be highly active.
ARTICLE IN PRESS
Anti-tuberculosis treatment and infliximab 651Discussion
Anti-TNF-a agents have been employed in recent
years to an increasing number of autoimmune
diseases. TNF-a is a cytokine produced mainly by
macrophages, which plays an important role in the
immune response to infections. It was recognized
early on, that reactivation of a latent TB infection
was one of the main side effects of the anti-TNF-a
agents. Therefore, when the use of these agents is
necessary, a chest radiograph and a PPD skin test
has been proposed as standard precautions.6 A PPD
skin test with at least 5mm of induration is
considered positive in these patients and therapy
with 300mg isoniazid daily for 9 months should be
given.7 TNF-a is essential in the formation of
granulomas,8 which is the basic defense mechanism
against tuberculosis. TB infection without forma-
tion of granulomas and extra-pulmonary or miliary
tuberculosis have been reported in patients treated
with anti-TNF-a agents.5,9 However, there is enough
evidence in the existing literature to suggest that
anti-TNF-a treatment, despite the immunosupres-
sion and subsequent susceptibility to TB, does not
always inhibit the formation of granulomas in
patients who eventually develop TB.5,10 In our
patient, the biopsy specimens, even in the first
bronchoscopy, when the long-lasting effect of
infliximab therapy was fully active, revealed case-
ating granulomas. This finding is in accordance with
the PPD skin test that was 9mm, and implies that
the cellular immunity was not fully suppressed by
infliximab.
Our case presentation was one of an unusual
clinical picture and course. The patient was
admitted with a fever that had begun only 24 h
previously, while his chest radiograph showed
advanced TB infection on both lungs. Such ad-
vanced lesions may be indicative of prior disease
activity of several weeks or months, which implies
that anti-TNF-a agents may be contributing to the
progression of a clinically silent disease.
The most interesting feature in this case was the
marked response delay to anti-TB therapy. The
patient displayed clinical and radiographic dete-
rioration during the first month of treatment, then
a slight improvement with a persistent fever until
the fourth month of therapy. The possibility of
resistance to any of the administered anti-TB drugs
that were given was excluded by BAL cultures and
consecutive sensitivity tests. Compliance to treat-
ment could be easily assessed as the patient was
treated as an in-patient for at least 4 months, until
he became afebrile. The delayed therapeutic
response in this patient was attributed to the
long-term immunosuppressive action of infliximab.The duration of this action is approximately 3
months, as can also be inferred from the fact that
the mean time to recurrence of ankylosing spondy-
litis, after discontinuation of infliximab, has been
estimated at 14 weeks.11 This parameter should
always be taken into account when treating such
patients, otherwise the suspicion of drug resistance
could lead to unwarranted modifications to the
treatment regimen.
Another remarkable feature in this case was the
reactivation of latent TB infection although the
patient had already been treated with isoniazid for
9 months. This observation implies that a 9-month
regimen of isoniazid does not offer a complete
protection from reactivation of TB. As a suggestion,
it may be prudent to prolong isoniazid treatment
for the duration of infliximab treatment, or to give
it in combination with other anti-TB drugs. Since a
limit has not been established for the duration of
treatment with infliximab in rheumatic diseases
and many patients have already been treated for
more than 3 years, the optimal regimen and
duration of treatment for latent TB infection
remains to be determined.References
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